We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
European authorities have approved Merck’s Gardasil, a vaccine which prevents cervical cancer and other potentially cancerous lesions caused by various strains of the human papillomavirus (HPV).
The long-running game of escalating bids for control of Croatian generic drugmaker Pliva appears to be over as Actavis has folded its hand and left Barr Pharmaceuticals as the only player at the table.
A nine-year-old federal program meant to stimulate pediatric clinical trials has been only partially successful, according to an article in the Sept. 13 edition of the Journal of the American Medical Association (JAMA).
Merck potentially faces more problems over its painkiller Vioxx, as researchers say they have found “increased renal and arrhythmia risks” from the drug and have confirmed cardiovascular risks.
More trouble is emerging for Merck over its painkiller Vioxx, as researchers say they have found “increased renal and arrhythmia risks” from the drug and have confirmed cardiovascular risks.
Evidence provided in Genta’s new drug application for Genasense shows that when the product is combined with two other compounds it produces increased response rates that are statistically, but perhaps not clinically, significant in patients with chronic lymphocytic leukemia, according to an FDA briefing paper.
The FDA’s approval of Barr Laboratories’ controversial Plan B contraceptive has removed Senate objections to Andrew von
Eschenbach’s nomination to be FDA commissioner but has landed the agency in more legal trouble.